Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) were up 9.2% during mid-day trading on Monday . The company traded as high as $3.55 and last traded at $3.44. Approximately 1,822,400 shares traded hands during mid-day trading, an increase of 177% from the average daily volume of 659,017 shares. The stock had previously closed at $3.15.

A number of analysts have recently issued reports on CPRX shares. HC Wainwright set a $6.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 22nd. Zacks Investment Research raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research note on Monday, August 13th. Oppenheimer set a $6.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 9th. BidaskClub raised Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Finally, ValuEngine lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $5.61.

The company has a market capitalization of $323.19 million, a PE ratio of -16.00 and a beta of 1.70.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.02. research analysts expect that Catalyst Pharmaceuticals Inc will post -0.29 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northern Trust Corp boosted its stake in Catalyst Pharmaceuticals by 9.7% during the second quarter. Northern Trust Corp now owns 1,107,944 shares of the biopharmaceutical company’s stock worth $3,458,000 after buying an additional 97,997 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Catalyst Pharmaceuticals by 15.7% during the second quarter. Bank of New York Mellon Corp now owns 274,813 shares of the biopharmaceutical company’s stock worth $858,000 after buying an additional 37,388 shares during the last quarter. Millennium Management LLC boosted its stake in Catalyst Pharmaceuticals by 16.5% during the second quarter. Millennium Management LLC now owns 1,610,176 shares of the biopharmaceutical company’s stock worth $5,024,000 after buying an additional 227,918 shares during the last quarter. MetLife Investment Advisors LLC acquired a new position in Catalyst Pharmaceuticals during the second quarter worth $157,000. Finally, Lido Advisors LLC boosted its stake in Catalyst Pharmaceuticals by 46.5% during the second quarter. Lido Advisors LLC now owns 87,506 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 27,766 shares during the last quarter. 51.49% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Company Profile (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3.

Recommended Story: How Do Tariffs Affect Trade Balances?

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.